Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRZ1 | P23471 | 4/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | RXRB | P28702 | 3/20 | 0.49 |
| ▸ | RXRG | P48443 | 3/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL11401460 | 0.96 | PTPRZ1 (0.59) | PTPRZ1PTPN1CA2CAMK2ARXRA | |
| Ethane SCHEMBL11271912 | 0.84 | PTPRZ1 (0.46) | PTPRZ1CA2CAMK2ARXRARXRB | |
| SCHEMBL9108524 | 0.83 | PTPRZ1 (0.61) | PTPRZ1PTPN1CA2LMNAHTT | |
| SCHEMBL13169964 | 0.83 | PTPRZ1 (0.61) | PTPRZ1PTPN1LMNATSHRHTT | |
| SCHEMBL11444608 | 0.81 | PTPRZ1 (0.44) | PTPRZ1CA2CAMK2ARXRARXRB | |
| SCHEMBL10655795 | 0.80 | PTPRZ1 (0.58) | PTPRZ1PTPN1LMNATSHRHTT | |
| Hydrochloric Acid SCHEMBL11269350 | 0.80 | PTPRZ1 (0.43) | PTPRZ1CA2CAMK2ARXRARXRB | |
| SCHEMBL8362761 | 0.79 | CA2 (0.58) | CA2CAMK2AAKR1B1ABCC4LMNA | |
| SCHEMBL2646892 | 0.79 | NR1H4 (0.51) | PTPRZ1PTPN1RXRARXRBRXRG | |
| SCHEMBL13946807 | 0.79 | PTPRZ1 (0.60) | PTPRZ1PTPN1LMNAGAANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-116023321-B | STING inhibitor prodrug and medical application thereof | 中国药科大学 | 2024-11-29 | — | — | CN | disclosed |
| CN-117756698-A | Urea compound and medical application thereof as STING inhibitor | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-116023321-A | STING inhibitor prodrug and medical application thereof | 中国药科大学 | 2023-04-28 | — | — | CN | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| EP-1366012-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| WO-2002064094-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| US-4970328-A | MITICIDE, FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
| US-4929642-A | MITICIDES, FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | GIPR, GLP1R, SIGMAR1 | PTPRZ1 2062/4885PTPN1 454/4885CA2 114/4885 |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | PTPRZ1 4532/4885PTPN1 4260/4885CA2 2361/4885 |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | PTPRZ1 1617/4885PTPN1 1526/4885CA2 3205/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | PTPRZ1 3713/4885PTPN1 4423/4885CA2 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.